MCM2 Expression in Different Molecular Subtypes of Epithelial Breast Cancers and its Association with Clinicopathological Parameters and Ki-67 Expression
Published: October 1, 2021 | DOI: https://doi.org/10.7860/JCDR/2021/50778.15580
Meghadipa Mandal, Anadi Roy Chowdhury, Susmita Mukhopadhyay
1. Junior Resident, Department of Pathology, R.G. Kar Medical College and Hospital, Kolkata, West Bengal, India.
2. Professor and Head, Department of Pathology, Murshidabad Medical College and Hospital, Berhampore, West Bengal, India.
3. Assistant Professor, Department of Pathology, R.G. Kar Medical College and Hospital, Kolkata, West Bengal, India.
Correspondence
Dr. Meghadipa Mandal,
Ac 1, Action Area 1, Farsight Housing Cooperative Society, New Town, North 24,
Parganas, Kolkata-700156, Bengal, India.
E-mail: meghadipa.mandal41@gmail.com
Introduction: Breast cancer is one of the most common malignancies, with few subtypes having a more aggressive outcome and resistance to conventional therapies, Triple Negative Breast Cancers (TNBCs) being one such variant. The Ki-67 lacks reproducibility and a standardised cut-off. MCM2 (Minichromosome Maintenance 2) has role in DNA repair and replication and its role as alternate marker for prognosis has been studied in this case.
Aim: To study MCM2 expression with respect to histologic grade, stage, nodal status and molecular subtypes of breast carcinoma. Also, to look for any correlation between Ki-67 and MCM2 expressions.
Materials and Methods: A cross-sectional, observational study conducted on a group of 20 patients who underwent mastectomy in a Tertiary Care Centre, R.G. Kar Medical College and Hospital, Kolkata, West Bengal, India, for a total duration of six months. Histologic grading, staging, nodal status was evaluated from Haematoxylin and Eosin (H&E) stained sections. Formalin-Fixed Paraffin-Embedded (FFPE) blocks suitable for Immunohistochemistry (IHC) were selected and MCM2, Estrogen Receptor (ER), Human Epidermal Growth Factor Receptor 2 (HER2), Progesterone Receptor (PR)/neu and Ki67 were performed. Scores given based on visual examination under light microscope. Analysis was done using IBM Statistical Package for the Social Sciences (SPSS) version 25.0 software.
Results: Most of the subjects belonged to 41-55 years age group. Statistical significance was seen between high MCM2 and Ki67 expressions (p-value=0.0171) and high histologic grade and TNBCs (p-value=0.009). High MCM2 and Ki-67 expressions also come with increased risk for advanced disease. High Ki-67 is also a risk predictor for lymph node positive cases. Positive correlation was seen between MCM2 and (R)= 0.4318.
Conclusion: The MCM2 is a predictor for adverse outcomes in breast carcinoma cases. It may serve as an alternative to Ki-67 as a proliferation marker, to guide clinicians in treatment strategies. Its role as a therapeutic target in aggressive breast carcinomas may be evaluated with larger study population in the future.
[
FULL TEXT ] | [ PDF]